Anti rbap46

anti-H3K27ac (Cat# 8173), anti-Batf (Cat# 8638), anti-H3K27me3 (Cat# 9733), anti-Mbd3 (Cat# 99169), anti-Chd3 (Cat# 4241), anti-Rbap46 (Cat# 6882), anti-Hdac1 (Cat# 34589), anti-Hdac2 (Cat# 57156), anti-EEA1 (Cat# 3288), anti-H3 (Cat# 4499), and anti-β-actin (Cat# 3700) were from Cell Signaling Technology (Danvers, USA). Anti-Kcnt2 (Cat# bs-12177R) was from Bioss Antibodies (Beijing, China). Anti-CD127 (A7R34), anti-c-Kit (2B8), anti-CD3 (17A2), anti-CD4 (GK1.5), anti-CD19 (1D3), anti-NK1.1 (PK136), anti-CD150 (mShad150), anti-CD34 (RAM34), anti-CD45 (30-F11), anti-CD90 (HIS51), anti-Sca-1 (D7), anti-CD25 (PC61.5), anti-Flt3 (A2F10), anti-α₄β₇ (DATK32), anti-RORγt (AFKJS-9), anti-NKp46 (29A1.4), anti-Gata3 (TWAJ), anti-KLRG1 (2F1), anti-PLZF (Mags.21F7), Lineage cocktail (88-7772-72), anti-CD48 (HM48-1), Anti-IL-17 (eBio17B7), and anti-CD16/32 (93) were purchased from eBiosciences (San Diego, USA). Anti-BrdU (600-401-C29) was purchased from ThermoFisher. Paraformaldehyde (PFA) and 4′,6-diamidino-2-phenylindole (DAPI) were from Sigma-Aldrich. The IL-17 ELISA kit was purchased from eBiosciences.

Immunoblotting was performed as described before^{3 (link)}. The following antibodies were used: anti-EZH2 (#5246, Cell Signaling Technology, Danvers, USA), anti-β-actin (A5441, Sigma Aldrich, St. Louis, USA), anti-H3 (ab1791, Abcam, Cambridge, UK), anti-H3K27me3 (#9733, Cell Signaling Technology, Danvers, USA), anti-SUZ12 (#3737, Cell Signaling Technology, Danvers, USA), anti-RbAP46 (#4522, Cell Signaling Technology, Danvers, USA), anit-EED (ab113911, Abcam, Cambridge, UK), anti-EZH1 (#42088, Cell Signaling Technology, Danvers, USA). Western blots were quantified using ImageJ version 1.50d and levels were normalized to the associated loading control (β-actin for EZH2, total H3 for H3K27me3).